---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-007395"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T09:19:53.161103+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nautilus Biotechnology enters $125M at-the-market equity offering with TD Cowen

## Summary
- Sales agreement with TD Cowen to sell up to $125M of common stock via ATM program.
- TD Cowen will receive up to 3.0% of gross proceeds as compensation.
- Company may set sale parameters including price, volume, and timing; no obligation to sell.
- Shares issued under S-3 registration statement filed Feb 28, 2024.

## SEC filing metadata
- accession: 0001628280-24-007395
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000162828024007395/0001628280-24-007395-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000162828024007395/naut-20240228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-007395
- JSON: https://secwatch.observer/filing/0001628280-24-007395.json
- Plain text: https://secwatch.observer/filing/0001628280-24-007395.txt

## Key facts
- Material Agreements
  Nautilus Biotechnology, Inc. entered into Sales Agreement with Cowen and Company, LLC valued at $125,000,000 (effective 2024-02-28).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Cowen and Company, LLC
  - Value: $125,000,000
  - Effective: 2024-02-28
  source text: On February 28, 2024, Nautilus Biotechnology, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Cowen and Company, LLC (“TD Cowen”) to sell shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having aggregate sales proceeds of up to $125,000,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808805/000162828024007395/0001628280-24-007395-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.